Cited by 141Neurobiology and Insect Physiology ResearchDevelopmental Biology and Gene RegulationBiochemical and Molecular Research

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

SYNTHETIC LETHALITY AND SEMI-LETHALITY AMONG FUNCTIONALLY RELATED MUTANTS OF DROSOPHILA MELANOGASTER

Open access

Lucchesi, John C·1968·Genetics

DOI 10.1093/genetics/59.1.37

Open this paper in CoChat — free account

Abstract

sex-linked mutant deep orange (dor) of Drosophila melanogaster is Tzonsible for a peculiar type of female sterility: mutant females produce no progeny when crossed to mutant males but yield some offspring (heterozygous daughters) when mated to wild-type males (MERRELL 1947). The effects of this mutant on embryonic development have been extensively studied by COUNCE (1956a) and more recently by HILDRETH and LUCCHESI (1967). In addition to the sterility phene, dor alters the pigmentation of the eyes (which are orange in color) and confers an abnormal spectrum of relative pteridine concentrations. An unusual characteristic of dor is that isoxanthopterin appears to be accumulated by mutant females (COUNCE 1957). During the course of preliminary investigations into the biochemical basis of dor female-sterility, art attempt was made to prevent the accumulation of isoxanthopterin in mutant females by genetic means. This resulted in the discovery of a highly specific synthetic lethal system involving dor and a non-allelic third chromosome mutant, rosy (ry) . The dor-ry system is similar to three other synthetic lethal systems, previously described in D. melanogaster: purpleoid (pd) and Purpleoider (Pdr) (BRIDGES 1922; as cited in BRIDGES and BREHME 1944) ; prune (pn) and Prune-killer (K-pn) ( STURTEVANT 1956) ; and Henna-recessiue-3 (Hnr3) and rosy (ry6) (TAIRA 1960; GOLDBERG, SCHALET and CHOVNICK 1962). A search was undertaken for the purpose of uncovering additional interactions among some of the mutants mentioned above. Since six of the latter affect eye color and/or pteridine levels, a number of other eye color mutants were tested. In addition, the female sterile mutant fused (fu) , similar in many respects to dor (although allowing lethal embryos to develop further than dor embryos (COUNCE 195613) ). was used in <some crosses. The results of these investigations are presented in this paper.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/genetics/59.1.37

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
Woolf, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,724
The mutants of drosophila melanogaster
Bridges, C. B., & Brehme, K. S. (1944) · Carnegie Institution of Washington eBooks · Cited by 321
Studies on female-sterility genes inDrosophila melanogaster
Counce, S. J. (1956) · Molecular Genetics and Genomics · doi:10.1007/bf00737163 · Cited by 72
BIOCHEMICAL DIFFERENCES BETWEEN THE MUTANTS ROSY-2 AND MAROON-LIKE OF DROSOPHILA MELANOGASTER
FORREST, H. S., Hanly, E. W., & Lagowski, J. M. (1961) · Genetics · doi:10.1093/genetics/46.11.1455 · Cited by 41
The Resolving Power of Genetic Fine Structure Analysis in Higher Organisms as Exemplified by Drosophila
Chovnick, A., Schalet, A., Kernaghan, R. P., & Talsma, J. (1962) · The American Naturalist · doi:10.1086/282236 · Cited by 22

Show all 5 references

Research works printed but not linked: 1

HapoRN, E., 1955 Letalfactoren in ihrer Bedeutung für Erbpathologie und Genphysiologie der Entwicklung. English translation, 1961, Wiley, N.Y.

Sorted by citations

The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,602
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,405
Rare and common variants: twenty arguments
Gibson, G. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3118 · Cited by 1,278
Synthetic lethality and cancer
O’Neil, N. J., Bailey, M. L., & Hieter, P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.47 · Cited by 689
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 546
Synthetic Genetic Array Analysis in Saccharomyces cerevisiae
Tong, A. H. Y., & Boone, C. M. (2005) · Humana Press eBooks · doi:10.1385/1-59259-958-3:171 · Cited by 489
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 490
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 431
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Zhu, H., Wei, M., Xu, J., Hua, J., Chen, L., Meng, Q., Zhang, Y., Liu, J., Zhang, B., Yu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01167-9 · Cited by 263
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 221
Synthetic Genetic Array (SGA) Analysis in Saccharomyces cerevisiae and Schizosaccharomyces pombe
Baryshnikova, A., Costanzo, M., Dixon, S. J., Vizeacoumar, F. J., Myers, C. L., Andrews, B., & Boone, C. M. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(10)70007-0 · Cited by 212
Synthetic lethality: exploiting the addiction of cancer to DNA repair
Shaheen, M. F., Allen, C., Nickoloff, J. A., & Hromas, R. (2011) · Blood · doi:10.1182/blood-2011-01-313734 · Cited by 207
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Gourley, C., Balmañà, J., Ledermann, J. A., Serra, V., Dent, R. A., Loibl, S., Pujade-Lauraine, É., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 195
Not just pretty eyes: Drosophila eye-colour mutations and lysosomal delivery
Lloyd, V. K., Ramaswami, M., & Krämer, H. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01270-7 · Cited by 165
Drugging the addict: non‐oncogene addiction as a target for cancer therapy
Nagel, R., Semenova, E. A., & Berns, A. J. M. (2016) · EMBO Reports · doi:10.15252/embr.201643030 · Cited by 161
Inbreeding: One word, several meanings, much confusion
Templeton, A. R., & Read, B. (1994) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8510-2_9 · Cited by 152
Targeted cancer therapies based on the inhibition of DNA strand break repair
O’Connor, M. J., Martin, N. M. B., & Smith, G. C. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210879 · Cited by 147
Genetic alteration of nerve membrane excitability in temperature-sensitive paralytic mutants of Drosophila melanogaster
Wu, C., & Ganetzky, B. (1980) · Nature · doi:10.1038/286814a0 · Cited by 145
Genes and networks regulating root anatomy and architecture
Wachsman, G., Sparks, E. E., & Benfey, P. N. (2015) · New Phytologist · doi:10.1111/nph.13469 · Cited by 138
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 140
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 123
Exploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 110
Searching for synthetic lethality in cancer
Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J., & Ashworth, A. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.009 · Cited by 107
Synthetic lethal approaches to breast cancer therapy
Rehman, F. L., Lord, C. J., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.172 · Cited by 104
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 108
Synthetic lethality: a framework for the development of wiser cancer therapeutics
Kaelin, W. G. (2009) · Genome Medicine · doi:10.1186/gm99 · Cited by 102
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
Montani, M. S. G., Prodosmo, A., Stagni, V., Merli, D., Monteonofrio, L., Gatti, V., Gentileschi, M. P., Barilà, D., & Soddu, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-95 · Cited by 97
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers
Belmontes, B., Slemmons, K. K., Su, C., Liu, S., Policheni, A. N., Moriguchi, J., Tan, H. L. E., Xie, F., Aiello, D. A., Yang, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0887 · Cited by 99
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
Morel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 87
Functional interactions between unlinked muscle genes within haploinsufficient regions of the Drosophila genome.
Homyk, T., & Emerson, C. P. (1988) · Genetics · doi:10.1093/genetics/119.1.105 · Cited by 81
Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma
Liao, C., Hu, L., & Zhang, Q. H. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00876-w · Cited by 84
Development of Synthetic Lethality Anticancer Therapeutics
Fang, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500415t · Cited by 73
BRCAness: a deeper insight into basal-like breast tumors
Summa, S. D., Pinto, R., Sambiasi, D., Petriella, D., Paradiso, V., Paradiso, A., & Tommasi, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt306 · Cited by 73
Taking on Challenging Targets: Making MYC Druggable
Horiuchi, D., Anderton, B. N., & Goga, A. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e497 · Cited by 67
Exploiting epigenetic vulnerabilities for cancer therapeutics
Mair, B., Kubicek, S., & Nijman, S. M. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.001 · Cited by 66
DNA repair as a shared hallmark in cancer and ageing
Clarke, T. L., & Mostoslavsky, R. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13285 · Cited by 74
Metabolic synthetic lethality in cancer therapy
Zecchini, V. R., & Frezza, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.12.003 · Cited by 63
Lethal combinations
Tucker, C. L., & Fields, S. (2003) · Nature Genetics · doi:10.1038/ng1103-204 · Cited by 60
Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”
Sharma, S. V., & Settleman, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.001 · Cited by 60
An intermittent approach for cancer chemoprevention
Wu, X., & Lippman, S. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3167 · Cited by 58
GENETIC FINE STRUCTURE OF THE Y CHROMOSOME OF DROSOPHILA HYDEI
Hackstein, J. H. P., Leoncini, O., Beck, H., Peelen, G. O. H., & Hennig, W. (1982) · Genetics · doi:10.1093/genetics/101.2.257 · Cited by 58
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
Bagnolini, G., Milano, D., Manerba, M., Schipani, F., Ortega, J. A., Gioia, D., Falchi, F., Balboni, A., Farabegoli, F., Franco, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01526 · Cited by 57
Chemoprevention – History and general principles
Wu, X., Patterson, S. L., & Hawk, E. T. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.012 · Cited by 57
The Isolation of Biological Rhythm Mutations on the Autosomes of Drosophila melanogaster
Jackson, F. R. (1983) · Journal of Neurogenetics · doi:10.3109/01677068309107068 · Cited by 56
SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines
Ehrenhöfer-Wölfer, K., Puchner, T., Schwarz, C., Rippka, J., Blaha-Ostermann, S., Strobl, U., Hörmann, A., Bader, G., Kornigg, S., Zahn, S. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48152-x · Cited by 51
Synthetic Lethality in Ovarian Cancer
Chandrasekaran, A., & Elias, K. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0500 · Cited by 41
Genetic Screening for Synthetic Lethal Partners of Polynucleotide Kinase/Phosphatase: Potential for Targeting SHP-1–Depleted Cancers
Mereniuk, T. R., Maranchuk, R. A., Schindler, A., Penner-Chea, J., Freschauf, G. K., Hegazy, S. A., Lai, R. L., Foley, E., & Weinfeld, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0939 · Cited by 40
Synthetic Lethal Vulnerabilities of Cancer
de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 43
Therapeutic targeting and patient selection for cancers with homologous recombination defects
Talens, F., Jalving, M., Gietema, J. A., & van Vugt, M. A. T. M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1322061 · Cited by 41
Circadian clock: Time for novel anticancer strategies?
Ercolani, L., Ferrari, A., Mei, C. D., Parodi, C., Wade, M. R., & Grimaldi, B. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.008 · Cited by 35
Synthetic lethality in lung cancer and translation to clinical therapies
Leung, A. W. Y., de Silva, T., Bally, M. B., & Lockwood, W. W. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0546-y · Cited by 35
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Eckardt, J., Stasik, S., Röllig, C., Sauer, T., Scholl, S., Hochhaus, A., Crysandt, M. M., Brümmendorf, T. H., Naumann, R., Steffen, B., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00790-1 · Cited by 37
Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges
Peng, S., Long, M., Chen, Q.-S., Yin, Z., Zeng, C., Zhang, W., Wen, Q., Zhang, X., Ke, W., & Wu, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02418-8 · Cited by 38
Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 35
Identification of synthetic lethal pairs in biological systems through network information centrality
Kranthi, T., Rao, S. B., & Manimaran, P. (2013) · Molecular BioSystems · doi:10.1039/c3mb25589a · Cited by 29
ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma
Chen, C., Shin, J. H., Eggold, J. T., Chung, M. K., Zhang, L. H., Lee, J., & Sunwoo, J. B. (2016) · Oncotarget · doi:10.18632/oncotarget.12210 · Cited by 29
The development of eggs produced by the female‐sterile mutant almondex of Drosophila melanogaster
Shannon, M. P. (1973) · Journal of Experimental Zoology · doi:10.1002/jez.1401830312 · Cited by 29
Clinical prospects of WRN inhibition as a treatment for MSI tumours
Morales-Juarez, D. A., & Jackson, S. P. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00319-y · Cited by 27
Synthetic lethal gene pairs: Experimental approaches and predictive models
Tang, S., Gökbağ, B., Fan, K., Shao, S., Huo, Y., Wu, X., Cheng, L., & Li, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.961611 · Cited by 28
Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer
Abbosh, P. H., & Plimack, E. R. (2018) · Bladder Cancer · doi:10.3233/blc-170129 · Cited by 26
Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
Li, K., You, J., Wu, Q., Meng, W., He, Q., Yang, B. R., Zhu, C., & Cao, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.002 · Cited by 26
Parallel universes of Black Six biology
Kraev, A. S. (2014) · Biology Direct · doi:10.1186/1745-6150-9-18 · Cited by 25
X-AUTOSOME INCOMPATIBILITIES IN DROSOPHILA MELANOGASTER: TESTS OF HALDANE'S RULE AND GEOGRAPHIC PATTERNS WITHIN SPECIES
Lachance, J., & True, J. (2010) · Evolution · doi:10.1111/j.1558-5646.2010.01028.x · Cited by 24
Lung-Cancer Chemoprevention by Induction of Synthetic Lethality in Mutant KRAS Premalignant Cells In Vitro and In Vivo
Huang, S., Ren, X., Wang, L., Zhang, L., & Wu, X. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0235 · Cited by 24
A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy
Bastos, I. F., Rebelo, S., & Silva, V. L. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116045 · Cited by 23
Enhancer of garnet/δAP-3 is a cryptic allele of thewhitegene and identifies the intracellular transport system for the white protein
Lloyd, V. K., Sinclair, D. A., Alperyn, M., & Grigliatti, T. A. (2002) · Genome · doi:10.1139/g01-139 · Cited by 19
Therapeutic Intervention by the Simultaneous Inhibition of DNA Repair and Type I or Type II DNA Topoisomerases: One Strategy, Many Outcomes
Węsierska‐Gądek, J., & Składanowski, A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.175 · Cited by 17
Isolation and characterization of the prune locus of Drosophila melanogaster.
Teng, D. H., Bender, L. B., Garrett-Engele, C. M., Tsubota, S. I., & Venkatesh, T. (1991) · Genetics · doi:10.1093/genetics/128.2.373 · Cited by 18
Exploiting the Nucleotide Substrate Specificity of Repair DNA Polymerases To Develop Novel Anticancer Agents
Crespan, E., Garbelli, A., Amoroso, A., & Maga, G. (2011) · Molecules · doi:10.3390/molecules16097994 · Cited by 17
Towards Post-Genomic Oncology: Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs
Mauro, A. D., Berretta, M., Santorsola, M., Ferrara, G., Picone, C., Savarese, G., & Ottaiano, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167723 · Cited by 19
Exploration of Synthetic Lethal Interactions as Cancer Drug Targets
Kuiken, H. J., & Beijersbergen, R. L. (2010) · Future Oncology · doi:10.2217/fon.10.131 · Cited by 16
Fine tuning chemotherapy to match BRCA1 status
Price, M. L., & Monteiro, Á. N. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.015 · Cited by 17
Application of the concept synthetic lethality toward anticancer therapy: A promise fulfilled?
Canaani, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.019 · Cited by 15
Natural products targeting cancer cell dependency
Shi, C., Yang, E. J., Tao, S., Ren, G., Mou, P. K., & Shim, J. S. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00438-x · Cited by 15
DNA Damage Response Pathways and Cancer
Ford, J. M., & Kastan, M. B. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00010-2 · Cited by 14
Lethal interactions of theeye-goneandeyelessmutants inDrosophila melanogaster
Hunt, D. M. (1970) · Genetics Research · doi:10.1017/s0016672300001348 · Cited by 14
The action of the geneprune (pn)inDrosophila melanogaster
Lifschytz, E., & Falk, R. (1969) · Genetics Research · doi:10.1017/s0016672300001841 · Cited by 14
Throwing a monkey wrench in the motor: Targeting DExH/D box proteins with small molecule inhibitors
Cencic, R., & Pelletier, J. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.01.008 · Cited by 15
Targeting “undruggable” c-Myc protein by synthetic lethality
Wang, C., Fang, H., Zhang, J., & Gu, Y. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0780-y · Cited by 13
Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models
Jiang, Z., Li, X., Xiao, Z., Gan, W., Zhang, X., Zhang, Y., Wang, W., Qinzhi, E., Huang, Y., Shi, Q., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02545-2 · Cited by 14
Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
Chen, H., Hu, Y., Zhuang, Z., Wang, D., Ye, Z., Ji, J., & Cheng, X. (2023) · Cancers · doi:10.3390/cancers15215114 · Cited by 12
The Population Genetics of X–Autosome Synthetic Lethals and Steriles
Lachance, J., Johnson, N., & True, J. (2011) · Genetics · doi:10.1534/genetics.111.131276 · Cited by 12
Exploiting replication stress for synthetic lethality in MYC-driven cancers
Zhang, Y. (2025) · American Journal of Cancer Research · doi:10.62347/rtvx8866 · Cited by 10
The role of Vps4 in cancer development
Huang, L. J., Zhan, S. T., Pan, Y., Bao, W., & Yang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203359 · Cited by 11
DNA repair pathways-targeted cyclovirobuxine inhibits castration-resistant prostate cancer growth by promoting cell apoptosis and cycle arrest
Gao, K., Zhu, S., Shao, Q., Qi, Y., Zhang, C., Li, X., Guo, J., Wu, G., & Jiang, H. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101708 · Cited by 10
Co-lethality studied as an asset against viral drug escape: the HIV protease case
Brouillet, S., Valère, T., Ollivier, E., Marsan, L., & Vanet, A. (2010) · Biology Direct · doi:10.1186/1745-6150-5-40 · Cited by 10
Functional genomics to explore cancer cell vulnerabilities
Kahle, K. T., Kozono, D., Ng, K., Hsieh, G., Zinn, P. O., Nitta, M., & Chen, C. C. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.10.focus09212 · Cited by 9
The role of PARP inhibitors in gastrointestinal cancers
Hanna, D., Chopra, N., Hochhauser, D., & Khan, K. H. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103621 · Cited by 9
DNA Damage Response Pathways and Cancer
Ford, J. M., & Kastan, M. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00011-6 · Cited by 9
Inhibition of RNA synthesis in Drosophila embryos by isoxanthopterin
Puckett, L., & Snyder, L. A. (1975) · Biochemical Genetics · doi:10.1007/bf00486001 · Cited by 9
ASTER: A Method to Predict Clinically Relevant Synthetic Lethal Genetic Interactions
Liany, H., Jayagopal, A., Huang, D., Lim, J. Q., Nur Izzah, N. B. H., Jeyasekharan, A. D. D., Ong, C. K., & Rajan, V. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3354776 · Cited by 12
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer
Schaule, J., Geeleher, P., Zuo, Z., Weichselbaum, R. R., Vokes, E. E., Fetscher, S., & Seiwert, T. Y. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.06.004 · Cited by 8
Challenges in Cancer Molecular Targets and Therapeutics
Wang, Y., & Giaccone, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00004 · Cited by 8
Dysfunctional β-cell longevity in diabetes relies on energy conservation and positive epistasis
Raval, K., Jamshidi, N., Seyran, B., Salwiński, Ł., Pillai, R. K., Yang, L., Ma, F., Pellegrini, M. A., Shin, J., Yang, X., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202402743 · Cited by 8
Targeting DNA Damage Repair Pathways Beyond PARP Inhibition
Merry, E., & Gourley, C. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01183-z · Cited by 8
Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2−ovarian cancers
Bueno, R., & Mar, J. C. (2017) · Methods · doi:10.1016/j.ymeth.2017.07.021 · Cited by 6
Cancer biology functional genomics: From small RNAs to big dreams
Rajan, S. S., Ludwig, K. R., Hall, K. L., Jones, T. L., & Caplen, N. J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23260 · Cited by 6
ASTER: A Method to Predict Clinically Actionable Synthetic Lethal Genetic InteractionsPreprint
Liany, H., Jeyasekharan, A. D. D., & Rajan, V. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.27.356717 · Cited by 6

Authors: Lucchesi, J. C.
Corresponding author: Lucchesi, John C
ORCID: Lucchesi, John C
Venue: Genetics
Publisher: Oxford University Press (OUP)
Published: 1968-05-01
Volume: 59
Issue: 1
Pages: 37-44
ISSN: 0016-6731 (ISSN-L)
1943-2631
DOI: 10.1093/genetics/59.1.37
OpenAlex: W2123596976
Cited by: 139
References: 5
Citations by year: 2026: 5 · 2025: 11 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 7 · 2012: 4
FWCI: 0.74
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: Genetics (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurobiology and Insect Physiology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords: synthetic lethality, female sterility, isoxanthopterin, pteridines, eye color mutants, Drosophila melanogaster, third chromosome
MeSH terms: Crosses, Genetic, Drosophila, Female, Genes, Lethal, Infertility, Female, Male, Mutation, Pigmentation, Pteridines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SYNTHETIC LETHALITY AND SEMI-LETHALITY AMONG FUNCTIONALLY RELATED MUTANTS OF DROSOPHILA MELANOGASTER

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks